{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T12:02:55Z","timestamp":1793534575347,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Non-alcoholic fatty liver disease (NAFLD) is a substantial contributor to liver-related morbidity worldwide, and yet, there are no standard, universal pharmacologic therapies approved for this indication. The aim of this systematic review and meta-analysis is to evaluate the effectiveness of SGLT-2 inhibitors in improving hepatic steatosis and hepatic fibrosis in patients with NAFLD. An extensive electronic database search was done to identify studies published from inception until\u00a0December 2023, without any language restrictions. All randomized controlled trials (RCT) that evaluated the use of SGLT-2 inhibitors for patients with NAFLD, regardless of diabetes mellitus status, were included. The Cochrane Risk of Bias 2.0 tool was used to assess the risk of bias of each study included. Evidence from all studies were synthesized as mean differences for continuous data, and as risk ratio for dichotomous outcomes. An inverse variance or Mantel\u2013Haenszel test was used in conjunction with a random-effects meta-analysis model, where necessary. 18 eligible RCTs involving 1330 participants were analyzed, all of which had risk of bias ranging from low to some concerns. Significant difference in means was observed for controlled attenuation parameter (6 trials, n\u2009=\u2009372; MD: \u2212\u00a010.59\u00a0dB\/m, 95% CI [\u2212\u00a018.25, \u2212\u00a02.92],\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.007, I\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u20090%); L\/S ratio (3 trials, n\u2009=\u2009163; MD: 0.11, 95% CI [0.01, 0.21],\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.04, I\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u200978%); LSM (7 trials, n\u2009=\u2009447; MD: \u2212\u00a00.67\u00a0kPa, 95% CI [\u2212\u00a01.19, \u2212\u00a00.16], p\u2009=\u20090.010, I\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u200969%); MRI-PDFF (5 trials, n\u2009=\u2009330; MD: \u2212\u00a02.61%, 95% CI [\u2212\u00a05.05, \u2212\u00a00.17],\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.04, I\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u200978%), and FIB-4 index (10 trials, n\u2009=\u2009648; MD: \u2212\u00a00.12, 95% CI [\u2212\u00a00.21, \u2212\u00a00.04],\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.005, I\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u200916%) after SGLT-2 inhibitor treatment as compared to controls. In conclusion, the use of SGLT-2 inhibitors may lead to slight improvement of hepatic steatosis and\/or fibrosis as compared to controls in patients with NAFLD and Type 2 diabetes mellitus based on imaging and histopathology biomarkers with low to moderate certainty of evidence.\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-52603-5","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T16:41:47Z","timestamp":1706114507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis"],"prefix":"10.1038","volume":"14","author":[{"given":"Albert Macaire C.","family":"Ong Lopez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine Audrei T.","family":"Pajimna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"key":"52603_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73\u201384 (2016).","journal-title":"Hepatology"},{"key":"52603_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1136\/bmjopen-2019-036663","volume":"10","author":"X Ge","year":"2020","unstructured":"Ge, X., Zheng, L., Wang, M., Du, Y. & Jiang, J. Prevalence trends in non-alcoholic fatty liver disease at the global, regional and National Levels, 1990\u20132017: A population-based observational study. BMJ Open 10, 8 (2020).","journal-title":"BMJ Open"},{"key":"52603_CR3","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi, Z. M. et al. The Global Epidemiology of NAFLD and Nash in patients with type 2 diabetes: A systematic review and meta-analysis. J. Hepatol. 71, 793\u2013801 (2019).","journal-title":"J. Hepatol."},{"key":"52603_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13578-020-00507-y","volume":"10","author":"X Li","year":"2020","unstructured":"Li, X. & Wang, H. Multiple organs involved in the pathogenesis of non-alcoholic fatty liver disease. Cell Biosci. 10, 1 (2020).","journal-title":"Cell Biosci."},{"key":"52603_CR5","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","volume":"66","author":"LA Adams","year":"2017","unstructured":"Adams, L. A., Anstee, Q. M., Tilg, H. & Targher, G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66, 1138\u20131153 (2017).","journal-title":"Gut"},{"key":"52603_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","volume":"129","author":"LA Adams","year":"2005","unstructured":"Adams, L. A. et al. The natural history of nonalcoholic fatty liver disease: A population-based Cohort Study. Gastroenterology 129, 113\u2013121 (2005).","journal-title":"Gastroenterology"},{"key":"52603_CR7","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/hep.23314","volume":"51","author":"C S\u00f6derberg","year":"2009","unstructured":"S\u00f6derberg, C. et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 51, 595\u2013602 (2009).","journal-title":"Hepatology"},{"key":"52603_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13098-016-0169-x","volume":"8","author":"T Jojima","year":"2016","unstructured":"Jojima, T. et al. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetol. Metabol. Syndrome 8, 1 (2016).","journal-title":"Diabetol. Metabol. Syndrome"},{"key":"52603_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1371\/journal.pone.0151511","volume":"11","author":"C Komiya","year":"2016","unstructured":"Komiya, C. et al. Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction. PLOS ONE 11, 3 (2016).","journal-title":"PLOS ONE"},{"key":"52603_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.14814\/phy2.14286","volume":"7","author":"A Tahara","year":"2019","unstructured":"Tahara, A. & Takasu, T. SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model. Physiol. Rep. 7, 22 (2019).","journal-title":"Physiol. Rep."},{"key":"52603_CR11","doi-asserted-by":"publisher","first-page":"204201882110002","DOI":"10.1177\/20420188211000243","volume":"12","author":"T Arai","year":"2021","unstructured":"Arai, T. et al. Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: A propensity score-matched analysis of real-world data. Therapeut. Adv. Endocrinol. Metabol. 12, 204201882110002 (2021).","journal-title":"Therapeut. Adv. Endocrinol. Metabol."},{"key":"52603_CR12","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3389\/fendo.2021.635556","volume":"12","author":"Q Wei","year":"2021","unstructured":"Wei, Q., Xu, X., Guo, L., Li, J. & Li, L. Effect of SGLT2 inhibitors on type 2 diabetes mellitus with non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials. Front. Endocrinol. 12, 256 (2021).","journal-title":"Front. Endocrinol."},{"key":"52603_CR13","first-page":"1456","volume":"2021","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 1456 (2021).","journal-title":"BMJ"},{"key":"52603_CR14","unstructured":"Advanced search results\u2014PUBMED. National Center for Biotechnology Information (2023, accessed 29 Dec 2023). https:\/\/pubmed.ncbi.nlm.nih.gov\/advanced\/."},{"key":"52603_CR15","unstructured":"Search manager: Cochrane Library. Search Manager|Cochrane Library (2023, accessed 29 Dec 2023).https:\/\/www.cochranelibrary.com\/advanced-search\/search-manager."},{"key":"52603_CR16","unstructured":"Embase. (2023, accessed 29 Dec 2023). https:\/\/www.embase.com\/landing?status=yellow."},{"key":"52603_CR17","unstructured":"American College of Physicians\u2014Advanced Search (2023, accessed 29 Dec 2023). https:\/\/www.acpjournals.org\/search\/advanced."},{"key":"52603_CR18","unstructured":"EPPI-Reviewer4 (V.4.14.2.0) [Computer program]. Evidence for Policy and Practice Information and Co-ordinating Centre. https:\/\/eppi.ioe.ac.uk\/cms\/Default.aspx?tabid=2914 (2022)."},{"key":"52603_CR19","unstructured":"Review Manager Web (RevMan Web) [Computer program]. The Cochrane Collaboration. https:\/\/revman.cochrane.org (2022)."},{"key":"52603_CR20","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1136\/bmj.l4898","volume":"2019","author":"JA Sterne","year":"2019","unstructured":"Sterne, J. A. et al. Rob 2: A revised tool for assessing risk of bias in randomised trials. BMJ 2019, 4898 (2019).","journal-title":"BMJ"},{"key":"52603_CR21","doi-asserted-by":"crossref","unstructured":"Higgins, J. P. et al. Cochrane Handbook for Systematic Reviews of Interventions (Cochrane Collaboration, 2019).","DOI":"10.1002\/9781119536604"},{"key":"52603_CR22","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1177\/0962280219889080","volume":"29","author":"S McGrath","year":"2020","unstructured":"McGrath, S. et al. Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis. Stat. Methods Med. Res. 29, 2520\u20132537 (2020).","journal-title":"Stat. Methods Med. Res."},{"key":"52603_CR23","unstructured":"GRADEpro GDT: GRADEpro Guideline Development Tool [Computer program]. Hamilton (ON): McMaster University (developed by Evidence Prime). https:\/\/www.gradepro.org (2022)."},{"key":"52603_CR24","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","volume":"12","author":"H Chehrehgosha","year":"2021","unstructured":"Chehrehgosha, H. et al. Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: A randomized, double-blind, placebo-controlled clinical trial. Diabetes Therapy 12, 843\u2013861 (2021).","journal-title":"Diabetes Therapy"},{"key":"52603_CR25","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1111\/jdi.13457","volume":"12","author":"KY Cho","year":"2020","unstructured":"Cho, K. Y. et al. Favorable effect of sodium\u2013glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone. J. Diabetes Investig. 12, 1272\u20131277 (2020).","journal-title":"J. Diabetes Investig."},{"key":"52603_CR26","first-page":"1067","volume":"9","author":"Y Chu","year":"2022","unstructured":"Chu, Y., Wang, D. & Lyu, Z. Effects of dapagliflozin combine with liraglutide on inflammatory factors, glucolipid metabolism and liver function in patients with type 2 diabetes combined with non-alcoholic fatty liver disease. Evalu. Anal. Drug-Use Hospit. China 9, 1067\u20131067 (2022).","journal-title":"Evalu. Anal. Drug-Use Hospit. China"},{"key":"52603_CR27","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.3390\/ph15121516","volume":"15","author":"SH Elhini","year":"2022","unstructured":"Elhini, S. H. et al. The impact of an SGLT2 inhibitor versus ursodeoxycholic acid on liver steatosis in diabetic patients. Pharmaceuticals 15, 1516 (2022).","journal-title":"Pharmaceuticals"},{"key":"52603_CR28","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","volume":"61","author":"JW Eriksson","year":"2018","unstructured":"Eriksson, J. W. et al. Effects of dapagliflozin and N-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: A double-blind randomised placebo-controlled study. Diabetologia 61, 1923\u20131934 (2018).","journal-title":"Diabetologia"},{"key":"52603_CR29","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3390\/jcm9010259","volume":"9","author":"E Han","year":"2020","unstructured":"Han, E., Lee, Y., Lee, B.-W., Kang, E. S. & Cha, B.-S. Ipragliflozin additively ameliorates non-alcoholic fatty liver disease in patients with type 2 diabetes controlled with metformin and pioglitazone: A 24-week randomized controlled trial. J. Clin. Med. 9, 259 (2020).","journal-title":"J. Clin. Med."},{"key":"52603_CR30","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1038\/s41591-022-01861-9","volume":"28","author":"SA Harrison","year":"2022","unstructured":"Harrison, S. A. et al. Licogliflozin for nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled, phase 2A study. Nat. Med. 28, 1432\u20131438 (2022).","journal-title":"Nat. Med."},{"key":"52603_CR31","first-page":"169","volume":"82","author":"CL Hu","year":"2020","unstructured":"Hu, C. L., Wang, Y. C., Xi, Y. & Yao, X. M. Dapagliflozin therapy curative effect observation on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Indian J. Pharmaceut. Sci. 82, 169 (2020).","journal-title":"Indian J. Pharmaceut. Sci."},{"key":"52603_CR32","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.2337\/dc17-0518","volume":"40","author":"D Ito","year":"2017","unstructured":"Ito, D. et al. Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: A randomized, 24-week, open-label, active-controlled trial. Diabetes Care 40, 1364\u20131372 (2017).","journal-title":"Diabetes Care"},{"key":"52603_CR33","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1111\/jdi.13279","volume":"11","author":"T Kinoshita","year":"2020","unstructured":"Kinoshita, T. et al. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-ARM, active control study. J. Diabetes Investig. 11, 1612\u20131622 (2020).","journal-title":"J. Diabetes Investig."},{"key":"52603_CR34","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","volume":"41","author":"MS Kuchay","year":"2018","unstructured":"Kuchay, M. S. et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: A randomized controlled trial (E-LIFT trial). Diabetes Care 41, 1801\u20131808 (2018).","journal-title":"Diabetes Care"},{"key":"52603_CR35","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/dom.13061","volume":"20","author":"T Shibuya","year":"2017","unstructured":"Shibuya, T. et al. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study. Diabetes Obes. Metabol. 20, 438\u2013442 (2017).","journal-title":"Diabetes Obes. Metabol."},{"key":"52603_CR36","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/dom.13520","volume":"21","author":"M Shimizu","year":"2018","unstructured":"Shimizu, M. et al. Evaluation of the effects of Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes. Metabol. 21, 285\u2013292 (2018).","journal-title":"Diabetes Obes. Metabol."},{"key":"52603_CR37","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","volume":"37","author":"H Taheri","year":"2020","unstructured":"Taheri, H. et al. Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: A randomized, double-blind, placebo-controlled trial. Adv. Therapy 37, 4697\u20134708 (2020).","journal-title":"Adv. Therapy"},{"key":"52603_CR38","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/hep4.1696","volume":"6","author":"H Takahashi","year":"2021","unstructured":"Takahashi, H. et al. Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD. Hepatol. Commun. 6, 120\u2013132 (2021).","journal-title":"Hepatol. Commun."},{"key":"52603_CR39","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.2337\/dc21-2049","volume":"45","author":"Y Takeshita","year":"2022","unstructured":"Takeshita, Y. et al. Comparison of Tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: A randomized, 48-week, open-label, active-controlled trial. Diabetes Care 45, 2064\u20132075 (2022).","journal-title":"Diabetes Care"},{"key":"52603_CR40","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3164\/jcbn.20-129","volume":"68","author":"H Tobita","year":"2021","unstructured":"Tobita, H. et al. Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: A prospective randomized study. J. Clin. Biochem. Nutr. 68, 173\u2013180 (2021).","journal-title":"J. Clin. Biochem. Nutr."},{"key":"52603_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjdrc-2020-001990","volume":"9","author":"M Yoneda","year":"2021","unstructured":"Yoneda, M. et al. Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (topind study): A randomized prospective open-label controlled trial. BMJ Open Diabetes Res. Care 9, 1 (2021).","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"52603_CR42","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313\u20131321 (2005).","journal-title":"Hepatology"},{"key":"52603_CR43","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","volume":"94","author":"EM Brunt","year":"1999","unstructured":"Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A. & Bacon, B. R. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 94, 2467\u20132474 (1999).","journal-title":"Am. J. Gastroenterol."},{"key":"52603_CR44","doi-asserted-by":"publisher","first-page":"114","DOI":"10.4239\/wjd.v10.i2.114","volume":"10","author":"H Raj","year":"2019","unstructured":"Raj, H. et al. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review. World J. Diabetes 10, 114\u2013132 (2019).","journal-title":"World J. Diabetes"},{"key":"52603_CR45","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1136\/bmjdrc-2020-001956","volume":"8","author":"S-C Shao","year":"2020","unstructured":"Shao, S.-C., Kuo, L.-T., Chien, R.-N., Hung, M.-J. & Lai, E.C.-C. SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: An umbrella review of Systematic Reviews. BMJ Open Diabetes Res. Care 8, 2 (2020).","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"52603_CR46","first-page":"6","volume":"37","author":"F dos Coelho","year":"2020","unstructured":"dos Coelho, F. et al. Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials. Diabetes\/Metabol. Res. Rev. 37, 6 (2020).","journal-title":"Diabetes\/Metabol. Res. Rev."},{"key":"52603_CR47","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/jdi.13237","volume":"11","author":"B Xing","year":"2020","unstructured":"Xing, B. et al. Effects of sodium\u2013glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. J. Diabetes Investig. 11, 1238\u20131247 (2020).","journal-title":"J. Diabetes Investig."},{"key":"52603_CR48","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/hepr.13645","volume":"51","author":"T Song","year":"2021","unstructured":"Song, T. et al. Meta-analysis of the effect of sodium\u2013glucose cotransporter 2 inhibitors on hepatic fibrosis in patients with type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease. Hepatol. Res. 51, 641\u2013651 (2021).","journal-title":"Hepatol. Res."},{"key":"52603_CR49","doi-asserted-by":"publisher","first-page":"288","DOI":"10.5114\/pg.2021.112365","volume":"17","author":"W Amjad","year":"2022","unstructured":"Amjad, W. et al. Sodium-glucose cotransporter-2 inhibitors improve liver enzymes in patients with co-existing non-alcoholic fatty liver disease: A systematic review and metanalysis. Gastroenterol. Rev. 17, 288\u2013300 (2022).","journal-title":"Gastroenterol. Rev."},{"key":"52603_CR50","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3389\/fendo.2021.615409","volume":"12","author":"J Lian","year":"2021","unstructured":"Lian, J. & Fu, J. Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: A meta-analysis. Front. Endocrinol. 12, 145 (2021).","journal-title":"Front. Endocrinol."},{"key":"52603_CR51","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1210\/clinem\/dgab578","volume":"107","author":"C Patel-Chavez","year":"2021","unstructured":"Patel-Chavez, C., Cusi, K. & Kadiyala, S. The emerging role of glucagon-like peptide-1 receptor agonists for the management of NAFLD. J. Clin. Endocrinol. Metabol. 107, 29\u201338 (2021).","journal-title":"J. Clin. Endocrinol. Metabol."},{"key":"52603_CR52","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2337\/dc23-S009","volume":"46","author":"NA ElSayed","year":"2022","unstructured":"ElSayed, N. A. et al. pharmacologic approaches to glycemic treatment: Standards of care in diabetes\u20142023. Diabetes Care 46, 140 (2022).","journal-title":"Diabetes Care"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52603-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52603-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52603-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T18:15:27Z","timestamp":1706120127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52603-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["52603"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-52603-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,24]]},"assertion":[{"value":"21 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2122"}}